新辅助化疗治疗晚期卵巢癌的疗效观察

Observation of the Efficacy of Neoadjuvant Chemotherapy in the Treatment of Advanced Ovarian Cancer

目的探讨新辅助化疗对晚期卵巢癌的治疗效果。方法随机选择2010年2月~2016年7月我院妇科收治的126例晚期卵巢癌患者,按照入院先后顺序随机分为研究组和对照组,各63例。研究组患者接受新辅助化疗联合肿瘤减灭术治疗,对照组患者接受肿瘤减灭术联合术后常规化疗,比较两组患者治疗效果。结果研究组患者有效率为73.02%,SD率为23.81%,PD率为3.17%,对照组患者有效率为66.67%,SD率为22.22%,PD率为11.11%,两组患者疗效比较,差异无统计学意义（P〉0.05）。研究组患者平均手术时间为（185.35±27.56）min,少于对照组的（236.55±64.31）min,差异具有统计学意义（t=42.338,P〈0.05）;研究组患者术中平均出血量为（467.33±77.41）ml,低于对照组的（556.34±82.28）ml,差异具有统计学意义（t=53.461,P〈0.05）。研究组患者残留肿瘤直径≤1 cm者38例（60.32%）,1~2 cm者20例（31.75%）,≥2 cm者5例（7.94%）,对照组患者残留肿瘤直径≤1 cm者20例（31.75%）,1~2 cm者21例（33.33%）,≥2 cm者22例（34.92%）。研究组肿瘤减灭率（〈1 cm）60.32%高于对照组的31.75%（P〈0.05）。结论新辅助化疗可缩小肿瘤体积,明显提高晚期卵巢癌肿瘤减灭率,减少术中出血。

Objective To study the effect of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer. Methods 126 cases of patients with advanced ovarian cancer were randomly selected from February 2010 to July 2016 in our department, according to admission order were randomly divided into research group and the control group, 63 cases each. Group patients received neoadjuvant chemotherapy combined treatment of tumor remove, control group patients received tumor combined postoperative routine chemotherapy to destroy loss, compared two groups of patients with therapeutic effect. Results The effective rate was 73.02% in patients with study group, SD rate was 23.81%, the PD rate was 3.17%, control group patients with effective rate of 66.67%, SD rate was 22.22%, the PD rate was 11.11%, there was no statistically significant difference effect in both groups（P〉0.05）. Team with the average operation time was（185.35±27.56） min, significantly less than the control group（236.55±64.31） min, statistically significant difference（t=42.338, P〈0.05）. Team average intraoperative blood loss in patients with for ml（467.33±77.41） ml, significantly lower than the control group（556.34±82.28） ml, statistically significant difference（t=53.461, P〈0.05）. Team in patients with residual tumor diameter 1 cm or less 38 cases（60.32%）, 20 cases（31.75%）, 1 ~ 2 cm, 2 cm or more in 5 cases（7.94%）, control group patients with residual tumor diameter 1 cm or less 20 cases（31.75%）, 1 ~ 2 cm 21 cases（33.33%）, 2 cm or higher 22 cases（34.92%）. The team tumor remove rate（ 1 cm） are significantly higher than 60.32% 31.75% in the control group（P〈0.05）. Conclusion Neoadjuvant chemotherapy can shrink the tumor volume, significantly increase the rate of advanced ovarian cancer tumor remove, reduce intraoperative bleeding.